Displaying 281 - 300 of 1557
FTC Approves Final Order Imposing Conditions on Stryker Corp.’s Acquisition of Wright Medical Group N.V.
Concurring Statement of Commissioner Christine S. Wilson Regarding the CBD Enforcement Actions
Statement of Commissioner Rohit Chopra Regarding CBD Enforcement Actions
Stryker and Wright Medical, In the Matter of
The Federal Trade Commission required medical device companies Stryker Corp. and Wright Medical Group N.V. to divest all assets related to Stryker’s total ankle replacements and finger joint implant products to remedy concerns, as alleged in the complaint, that Stryker’s proposed $4 billion acquisition of Wright would harm competition in these two markets. Under the consent order, Stryker and Wright must divest all assets associated with Stryker’s total ankle replacements and finger joint implants to DJO Global, allowing it to become an independent, viable, and effective competitor in these markets. After a period for public comment, the Commission issued its final order on December 11, 2020.
Company that Provides Travel Emergency Services Settles FTC Allegations it Failed to Secure Sensitive Consumer Data
FTC Sends 28 Warning Letters Regarding Agency’s Eyeglass Rule
FTC Challenges Hackensack Meridian Health, Inc.’s Proposed Acquisition of Competitor Englewood Healthcare Foundation
FTC Approves Otto Bock HealthCare North America, Inc.’s Application to Divest Assets It Gained through Acquisition of FIH Group Holdings, LLC
A.S. Research, LLC (Synovia)
The marketers of a dietary supplement called Synovia agreed to settle FTC charges by halting the deceptive tactics they allegedly used to mislead consumers into thinking Synovia could treat arthritis and alleviate joint pain. In December 2020, the Commission announced it was returning almost $775,000 to consumers who both the deceptively marketed product.
Otto Bock HealthCare North America, Inc., In the Matter of
The FTC issued an administrative complaint challenging the merger of two prosthetics manufacturers that are top sellers of prosthetic knees equipped with microprocessors. According to the FTC’s complaint, Otto Bock’s consummated acquisition of FIH Group Holdings (owner of Freedom Innovations) harmed competition in the U.S. market for microprocessor prosthetic knees by eliminating head-to-head competition between the two companies, removing a significant and disruptive competitor, and entrenching Otto Bock’s position as the dominant supplier. Microprocessor knees, which use microprocessors to adjust the stiffness and positioning of the joint in response to variations in walking rhythm and ground conditions, provide a stable platform for amputees. Compared to other products, microprocessor prosthetic knees reduce the risk of falling, cause less pain, and promote the health and function of the sound limb. In addition to issuing an administrative complaint, the Commission authorized agency staff to seek a temporary restraining order, preliminary injunction, and ancillary relief in federal court, should doing so be necessary to ensure the Freedom Innovations business remains viable and to preserve the Commission ability to order effective relief. On Dec. 1, 2020, the Commission announced approval for the divestiture of the Freedom assets.
Statement of Commissioner Christine S. Wilson, Joined by Commissioner Noah Joshua Phillips, In the Matter of Methodist Le Bonheur Healthcare
FTC Sues to Block Proposed Acquisition of Two Memphis-Area Hospitals
Pfizer Inc. and Mylan N.V.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
PrivacyCon 2021
Stryker and Wright Medical; Analysis of Consent Orders To Aid Public Comment
Sunday Riley Modern Skincare, LLC; In the Matter of
On October 21, 2019, the FTC announced it had halted the deceptive online marketing tactics of cosmetics firm Sunday Riley Modern Skincare, LLC and its CEO. Under the order settling the FTC’s complaint the defendants were banned from misleading consumers by posting fake reviews of the company’s products on a major retailer’s website, at the CEO’s direction, and by failing to disclose that the reviewers were company employees. The FTC announced approval of the final order in November 2020.
Statement of Commissioner Rohit Chopra in the Matter of Stryker and Wright Medical
FTC Requires Medical Device Companies Stryker Corp. and Wright Medical Group N.V. to Divest Assets to Preserve Competition
Statement of Commissioner Christine S. Wilson in the Matter of Pfizer Inc./Mylan N.V.
Displaying 281 - 300 of 1557